Annexon to Participate in Upcoming June Investor Conferences
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced that president and CEO Douglas Love will join fireside chats at two June 2026 investor conferences.
He will appear at the Jefferies Global Healthcare Conference on June 3, 2026 at 11:40 a.m. ET in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026 at 8:00 a.m. ET in Miami Beach. Live webcasts and 30-day replays will be available in the Events & Presentations section of Annexon’s investor website.
Positive
- None.
Negative
- None.
News Market Reaction – ANNX
In the May 27 session, ANNX declined 2.36%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Inducement grants | Negative | -1.0% | Equity inducement option grants under Nasdaq Listing Rule 5635(c)(4). |
| May 07 | Q1 2026 earnings | Positive | +3.1% | Quarterly results, cash of $225.0 million and 2026 pipeline milestones. |
| May 06 | Conference presentation | Neutral | -0.3% | Presentation at Bank of America Securities Health Care Conference 2026. |
| Apr 08 | Conference presentation | Neutral | +1.5% | Needham Virtual Healthcare Conference presentation and webcast availability. |
| Mar 30 | FY 2025 earnings | Positive | +11.7% | Full-year 2025 results, cash $238.3 million and 2026 milestones. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news, including earnings and conference participation, has generally seen price moves align directionally with the tone of the announcements.
Over the last few months, Annexon has paired financial updates with steady visibility efforts. Q4 2025 and Q1 2026 results highlighted late-stage pipeline progress and cash positions of $238.3 million and $225.0 million, with shares reacting positively (11.69% and 3.08%). In parallel, multiple conference presentations (Needham, Bank of America) and inducement grants drew smaller moves. The new June conference appearances continue this pattern of active investor engagement without new clinical or financial data.
Key Terms
immunotherapies medical
neuroinflammatory medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, Esq., president & chief executive officer, will participate in fireside chats during the following June investor conferences:
- Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 11:40 a.m. ET in New York, NY; and,
- Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026, at 8:00 a.m. ET in Miami Beach, FL.
Live webcasts of the presentations can be accessed under the ‘Events & Presentations’ section on the Investors page at annexonbio.com. Replays of the webcasts will be archived on the Annexon website for 30 days following the presentations.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
